TNF and inflammatory bowel disease: Current advanced therapies for moderate to severe IBDs such as biologic agents (anti-TNFα, anti IL12/23, anti-IL-23, and anti-integrins) and small molecules (JAK inhibitors and anti-S1P) have improved the therapeutic armamentarium available to IBD physicians, however, their use is limited by adverse effects, high costs, and a ceiling of effectiveness.